Skip to main content

Table 2 Weighted mean validation measures for categorical variables in Report of Verified Case of Tuberculosis (RVCT)

From: Assessing the validity of tuberculosis surveillance data in California

#*

RVCT Variable

Concordance (95% CI) %

Sensitivity of Reported Value (95% CI) %

Predictive Value of Reported Positive Value (95% CI) %

 

DEMOGRAPHIC

1

Sex

98.1

(96.7, 99.0)

99.7

(98.0, 99.9)

97.5

(95.3, 98.6)

2

Race

97.7

(96.3, 98.6)

ND

ND

ND

ND

 

   White

ND

ND

99.2

(97.5, 99.7)

97.0

(94.4, 98.4)

 

   Black

ND

ND

95.3

(87.1, 98.4)

97.9

(88.8, 99.7)

 

   Asian-Pacific Islander

ND

ND

97.5

(94.9, 98.8)

98.4

(96.3, 99.3)

 

   American Indian/Alaska Native

ND

ND

50.0

(12.8, 87.2)

100.0

-§

3

Ethnicity

98.5

(97.2, 99.1)

97.6

(94.7, 98.9)

98.1

(95.5, 99.2)

 

Country of origin

      

4

   U.S.-born

98.9

(97.7, 99.4)

99.1

(95.1, 99.9)

96.6

(92.8, 98.4)

5

   Other country of origin

96.0

(93.6, 97.5)

ND

ND

ND

ND

6

Occupation

84.4

(80.7, 87.5)

ND

ND

ND

ND

 

   Health care worker

ND

ND

78.2

(46.4, 93.7)

70.5

(41.3, 89.0)

 

   Migratory agricultural worker

ND

ND

51.8

(25.1, 77.5)

81.1

(38.3, 96.7)

 

   Other occupation

ND

ND

76.4

(69.8, 81.9)

89.0

(83.3, 92.9)

 

   Not employed within past 24 months

ND

ND

93.5

(89.5, 96.0)

82.2

(76.9, 86.5)

7

Resident of long-term care facility at diagnosis

98.3

(97.1, 99.0)

67.8

(47.1, 83.3)

76.8

(57.8, 88.9)

8

Resident of correctional facility at diagnosis

99.0

(97.7, 99.6)

69.7

(45.7, 86.3)

100.0

-

 

SOCIAL AND BEHAVIORAL RISK FACTORS

9

Homeless within past 1–2 years||

99.1

(96.9, 99.7)

97.3

(92.6, 99.0)

95.1

(75.9, 99.2)

10

Injecting drug user within past year

98.1

(96.5, 99.0)

63.5

(41.5, 81.0)

86.5

(59.8, 96.5)

11

Non-injecting drug user within past year

96.6

(94.6, 97.9)

70.1

(55.2, 81.7)

90.9

(74.6, 97.1)

12

Excess alcohol use within past year

91.8

(88.8, 94.0)

69.9

(61.0, 77.6)

96.8

(89.3, 99.1)

 

DIAGNOSTIC AND CLINICAL

13

Previous TB

94.6

(92.3, 96.2)

57.6

(45.0, 69.3)

93.5

(81.9, 97.9)

14

Site of disease

92.5

(90.4, 94.2)

ND

ND

ND

ND

 

   Pulmonary only

ND

ND

96.7

(94.6, 97.9)

96.2

(94.3, 97.4)

 

   Extra-pulmonary only

ND

ND

98.6

(96.8, 99.4)

81.6

(74.4, 87.0)

 

   Both pulmonary and extra-pulmonary

ND

ND

51.1

(39.7, 62.4)

86.9

(73.9, 94.0)

15

Sputum smear

89.6

(86.0, 92.3)

90.5

(85.8, 93.7)

92.2

(87.9, 95.1)

16

Sputum culture

96.8

(94.2, 98.2)

100.0

-

96.8

(94.2, 98.2)

17

Smear of tissue/body fluids (non-sputum)

49.2

(38.4, 60.0)

31.2

(21.0, 43.6)

98.7

(98.1, 99.2)

18

   Tissue/body fluid type (non-sputum)

76.4

(59.3, 87.8)

ND

ND

ND

ND

19

Culture of tissue/body fluid (non-sputum)

98.2

(94.6, 99.4)

100.0

-

98.2

(94.6, 99.4)

20

   Tissue/body fluid type (non-sputum)

73.9

(66.0, 80.6)

ND

ND

ND

ND

 

Chest x-ray

      

21

   Abnormal/normal

96.0

(94.0, 97.3)

99.1

(97.6, 99.7)

96.8

(94.8, 98.0)

22

   If abnormal: cavitary/non-cavitary**

90.9

(88.0, 93.2)

75.1

(66.3, 82.3)

86.2

(78.0, 91.7)

23

   If abnormal: stable/worsening/improving

46.8

(37.0, 56.9)

ND

ND

ND

ND

 

Stable

ND

ND

49.9

(36.0, 63.7)

53.7

(39.0, 67.9)

 

Worsening

ND

ND

52.0

(38.0, 65.7)

51.7

(37.8, 65.4)

 

Improving

ND

ND

26.9

(8.7, 58.6)

19.8

(6.5, 46.8)

24

Initial drug susceptibility testing done

100.0

-

100.0

-

100.0

-

 

Results of initial drug susceptibility testing††

      

25

   Isoniazid

99.2

(98.1, 99.7)

92.5

(82.6, 97.0)

100.0

-

26

   Rifampin

100.0

-

100.0

-

100.0

-

27

   Pyrazinamide

92.1

(89.3, 94.2)

88.1

(68.8, 96.1)

100.0

-

28

   Ethambutol

100.0

-

100.0

-

100.0

-

29

   Streptomycin

98.3

(96.8, 99.1)

93.2

(78.8, 98.0)

92.0

(78.7, 97.3)

 

TREATMENT AND CASE MANAGEMENT

 

Initial treatment regimen

      

30

   Isoniazid

98.2

(96.8, 99.0)

99.6

(98.8, 99.9)

98.6

(97.2, 99.3)

31

   Rifampin

98.7

(97.5, 99.4)

99.9

(99.7, 100.0)

98.8

(97.6, 99.4)

32

   Pyrazinamide

96.7

(95.1, 97.8)

98.1

(96.7, 98.9)

98.4

(97.1, 99.1)

33

   Ethambutol

95.9

(94.0, 97.2)

98.8

(97.4, 99.4)

96.5

(94.6, 97.8)

34

   Streptomycin

98.7

(97.7, 99.3)

40.3

(16.3, 70.1)

38.1

(14.1, 69.9)

35

Sputum culture conversion documented

85.4

(81.1, 88.8)

93.3

(89.5, 95.7)

87.8

(83.0, 91.3)

36

Reason therapy stopped‡‡

97.9

(96.4, 98.8)

ND

ND

ND

ND

 

   Completion of therapy

ND

ND

97.8

(96.0, 98.8)

100.0

-

 

   Lost/uncooperative or refused therapy

ND

ND

98.4

(98.4, 98.4)

62.9

(46.1, 77.1)

 

   Died

ND

ND

99.2

(96.6, 99.8)

93.3

(84.2, 97.4)

37

Provider type

73.4

(69.8, 76.7)

ND

ND

ND

ND

 

   Health Department only (HD)

ND

ND

74.7

(69.7, 79.1)

90.3

(86.7, 93.0)

 

   Private/Other only

ND

ND

79.6

(74.6, 83.9)

80.0

(74.2, 84.8)

 

   Both HD and Private/Other

ND

ND

38.6

(26.4, 52.5)

18.1

(12.0, 26.4)

38

Therapy administration

48.6

(44.4, 52.8)

ND

ND

ND

ND

 

   Directly Observed Therapy (DOT) only

ND

ND

29.7

(10.5, 60.4)

1.1

(0.4, 2.9)

 

   Self-administered Therapy (SAT) only

ND

ND

72.0

(66.7, 76.7)

88.3

(83.1, 92.0)

 

   Both DOT and SAT

ND

ND

26.4

(21.3, 32.2)

82.7

(73.1, 89.4)

39

Final drug susceptibility testing done ‡‡

100.0

-

100.0

-

100.0

-

 

Results of final drug susceptibility testing††§§

      

40

   Isoniazid

100.0

-

100.0

-

100.0

-

41

   Rifampin

98.4

(97.3, 99.0)

92.6

(79.7, 97.5)

100.0

-

42

   Pyrazinamide

90.5

(59.5, 98.4)

-

-

-

-

43

   Ethambutol

90.3

(59.0, 98.4)

-

-

-

-

44

   Streptomycin

100.0

-

100.0

-

100.0

-

  1. Note: All results are presented as survey-weighted mean estimates for the statewide cohort from which the sample was drawn.
  2. * Variable number (see Table 1)
  3. † Confidence interval
  4. ‡ Not determined, by design
  5. § No value computed (e.g., division by 0)
  6. || RVCT defines homeless within 1 year of diagnosis; medical record review defined homeless within 2 years of diagnosis
  7. ** RVCT values: cavitary, non-cavitary consistent with TB, non-cavitary not consistent with TB; medical record review values: cavitary, abnormal/non-cavitary
  8. †† As a result of a very small number of second-line drug susceptibility test results, these results are not presented.
  9. ‡‡ Excludes 9 cases: 1 case without TB; 5 cases reported as 'moved' on RVCT; 3 cases reported as 'other" on RVCT
  10. §§ Based on small number of cases with final susceptibility testing performed; therefore estimates are subject to considerable instability